13-Cis-retinoic acid: Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer

Frank L. Meyskens, Gary E. Goodman, David S Alberts, Loretta Marie Itri

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology and been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.

Original languageEnglish (US)
Pages (from-to)75-101
Number of pages27
JournalCritical Reviews in Oncology/Hematology
Volume3
Issue number1
DOIs
StatePublished - 1985

Fingerprint

Isotretinoin
Clinical Pharmacology
Toxicology
Neoplasms
Therapeutics
Skin
Retinoids
Immunologic Factors
Tissue Distribution
Half-Life
Histology
Animal Models
Pharmacokinetics
Pharmacology

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

13-Cis-retinoic acid : Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. / Meyskens, Frank L.; Goodman, Gary E.; Alberts, David S; Itri, Loretta Marie.

In: Critical Reviews in Oncology/Hematology, Vol. 3, No. 1, 1985, p. 75-101.

Research output: Contribution to journalArticle

@article{ffbd50cf96b6489aafced0d99c1c044d,
title = "13-Cis-retinoic acid: Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer",
abstract = "Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology and been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.",
author = "Meyskens, {Frank L.} and Goodman, {Gary E.} and Alberts, {David S} and Itri, {Loretta Marie}",
year = "1985",
doi = "10.1016/S1040-8428(85)80040-8",
language = "English (US)",
volume = "3",
pages = "75--101",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - 13-Cis-retinoic acid

T2 - Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer

AU - Meyskens, Frank L.

AU - Goodman, Gary E.

AU - Alberts, David S

AU - Itri, Loretta Marie

PY - 1985

Y1 - 1985

N2 - Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology and been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.

AB - Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology and been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.

UR - http://www.scopus.com/inward/record.url?scp=0022259707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022259707&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(85)80040-8

DO - 10.1016/S1040-8428(85)80040-8

M3 - Article

C2 - 3893773

AN - SCOPUS:0022259707

VL - 3

SP - 75

EP - 101

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -